CIP
PTCT icon

Convergence Investment Partners’s PTC Therapeutics PTCT Stock Holding History

Convergence Investment Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
21,727
-5,492
-20% -$397K 0.17% 173
2026
Q1 		$1.85M Buy
27,219
+26
+0.1% +$1.84K 0.3% 117
2025
Q4 		$2.07M Sell
27,193
-735
-3% -$53.4K 0.41% 77
2025
Q3 		$1.71M Buy
27,928
+3,249
+13% +$169K 0.38% 83
2025
Q2 		$1.21M Buy
+24,679
New +$1.17M 0.31% 122

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Convergence Investment Partners's PTCT Position: Q2 2026 in Review

Convergence Investment Partners reduced its PTC Therapeutics (PTCT) stake by 20% in Q2 2026, selling an estimated $397K and leaving 21,727 shares worth $1.77M. The position accounts for 0.17% of the portfolio, ranked #173.

Convergence Investment Partners first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.07M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Convergence Investment Partners held 21,727 shares of PTC Therapeutics worth $1.77M as of Q2 2026.
  • Convergence Investment Partners sold 5,492 PTC Therapeutics shares in Q2 2026, an estimated $397K.
  • PTC Therapeutics made up 0.17% of Convergence Investment Partners's portfolio in Q2 2026, its #173 holding.
  • Convergence Investment Partners first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Convergence Investment Partners's PTC Therapeutics position peaked at $2.07M in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.